Articles in this section

• Hepatitis C cure, sofosbuvir, turns 5 years old: The vast majority of people still have not been treated

  

  Advocates scandalized that Gilead’s hepatitis C profits have raked in US$25.8 billion, which could have treated everyone while still earning US$16 billion in profits.
  6 December 2018, Paris, France, New York, NY— People living with hepatitis C, access to medicines activists, and the medical (...) More

  6 December 2018

• APN+ joins MTAAG+ in congratulating Malaysia on sofosbuvir compulsory license CL ends Gilead’s dangerous games with lives of HepC patients in Malaysia Result of hard fought efforts of community-based groups, NGOs and treatment providers

  20 September 2017, Bangkok and Kuala Lumpur: The Asia-Pacific Network of People living with HIV (APN+) joins the Positive Malaysian Treatment Access and Advocacy Group (MTAAG+) in welcoming the approval of a government use license (also known as compulsory license or CL) in Malaysia for (...) More

  6 October 2017

• Hepatitis C: Gilead patent on sofosbuvir partially maintained following MdM patent opposition Paris, October 5th 2016

  

  European Patent Office (EPO) has taken its decision following Doctors of the World - Médecins du Monde (MdM) patent opposition on Gilead Sciences’ Sofosbuvir. MdM applauds EPO’s decision to revoke partially the patent.
  MdM has filled an opposition on the patent granted to Gilead Sciences for (...) More

  5 October 2016

• Hepatitis C: no more treatment rationing; universal access to generic medicines everywhere! 16 April 2016

  

  Find below some pictures of the demonstration as well as videos in english and in spanish
  Barcelona – People with hepatitis C virus (HCV) and their allies from Spain and around the world have gathered at the International Liver Congress to protest the outrageous price of life-saving HCV (...) More

  21 April 2016

• Gilead: Stop Blocking Access to Hepatitis C Treatment Thousands of activists urge company to change its policies on eve of shareholder meeting

  

  New York, May 5, 2015 — On the eve of pharmaceutical company Gilead Sciences’ annual shareholder meeting, thousands of people who have hepatitis C virus (HCV) and HCV/HIV coinfection, with their allies and physicians, have demanded that Gilead change its policies that deny access to treatment for (...) More

  5 May 2015